90050-52-5

Basic information

• Product Name: 3-Bromo-N-methyl-5-nitrobenzamide
• Synonyms: 3-Bromo-N-methyl-5-nitrobenzamide;3-Bromo-N-methyl-5-nitrobenzamide 98%;N-Methyl 3-bromo-5-nitrobenzamide;3-Bromo-N-methyl-5-nitrobenzamide98%
• CAS NO: 90050-52-5
• Molecular Formula: C₈H₇BrN₂O₃
• Molecular Weight: 259.05678
• Product Categories: blocks;Bromides;Carboxes;NitroCompounds
• Mol File: 90050-52-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 353.343 °C at 760 mmHg
• Flash Point: 167.496 °C
• Appearance: /
• Density: 1.641 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-Bromo-N-methyl-5-nitrobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-N-methyl-5-nitrobenzamide(90050-52-5)
• EPA Substance Registry System: 3-Bromo-N-methyl-5-nitrobenzamide(90050-52-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 90050-52-5(Hazardous Substances Data)

Usage

General Description

3-Bromo-N-methyl-5-nitrobenzamide is a chemical compound with the molecular formula C8H7BrN2O3. It is a yellow crystalline solid that is commonly used in pharmaceutical and research applications. 3-Bromo-N-methyl-5-nitrobenzamide is a derivative of benzamide and contains a bromine atom, a methyl group, and a nitro group attached to the benzene ring. It has been found to have potential biological activity and may be used in the development of new drugs or as a research tool for studying various biochemical processes. Additionally, it may have applications in the synthesis of other organic compounds due to its unique structure and reactivity.

InChI:InChI=1/C8H7BrN2O3/c1-10-8(12)5-2-6(9)4-7(3-5)11(13)14/h2-4H,1H3,(H,10,12)

Upstream product

• 6307-83-1 3-bromo-5-nitro-benzoic acid 
• 74-89-5 methylamine 
• 121-92-6 3-nitrobenzoic acid 
• 51339-40-3 3-bromo-5-nitrobenzoyl chloride 

Downstream Products

• 675122-46-0 5-(3-bromo-5-nitrophenyl)-1-methyl-1H-tetraazole 
• 1445790-17-9 3-(cyclopent-1-en-1-yl)-N-methyl-5-nitrobenzamide 
• 675122-48-2 3-Ethyl-5-(1-methyl-1H-tetrazole-5-yl)aniline 
• 675122-47-1 1-methyl-5-(3-nitro-5-vinylphenyl)-1H-tetraazole 
• 852661-64-4 N-((1R,2S)-3-{cyclohexyl[3-(4-fluorophenyl)propyl]amino}-2-hydroxy-1-methylpropyl)-N'-[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]urea 
• 852660-57-2 N-[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]-N'-((1R,2S)-2-{[((2RS)-6-fluoro-1,2,3,4-tetrahydronaphthalen-2-yl)(methyl)amino]methyl}cyclohexyl)urea 
• 852660-52-7 N-[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]-N'-((1R,2S)-2-{[((2RS)-6-fluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino]methyl}cyclohexyl)urea 
• 852660-89-0 N-{(1R,3R,4S)-4-{[[2,2-dimethyl-3-(4-fluorophenyl)propyl](methyl)amino]methyl}-3-[({[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]amino}carbonyl)amino]cyclohexyl}-N-methylacetamide 
• 675122-49-3 phenyl 3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenylcarbamate 

Relevant articles and documents

SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS

Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.

Substituted fused bicyclic amines as modulators of chemokine receptor activity

The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5′, R6, a, b, c, d, and u are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.